Combinations of pembrolizumab and targeted therapies for advanced clear cell kidney cancer
The KEYMAKER-U03 study is looking at different combinations of immunotherapy [...]
New treatment for pretreated advanced kidney cancer shows promise
A new treatment, called NDI-101150 has been shown to be [...]
New cancer vaccine in development
A new vaccine is being heralded as a 'game changer’ [...]
Adjuvant pembrolizumab prolongs overall survival for kidney cancer patients
Surgery (partial or radical nephrectomy) is the standard of care [...]
Lenvatinib plus pembrolizumab for advanced kidney cancer
The final survival information from the phase 3 CLEAR study [...]
Patient’s perspective on pembrolizumab/lenvatinib for kidney cancer
In 2009, Cesar Fuentes was first diagnosed with kidney cancer [...]
Pembrolizumab plus lenvatinib for non-clear cell kidney cancer
Immunotherapy combinations are becoming the standard treatment for people with [...]
Pembrolizumab plus lenvatinib as first-line treatment for advanced non-clear cell kidney cancer
Immunotherapy combinations are becoming the standard treatment after surgery for [...]
Adjuvant therapy for kidney cancer
Adjuvant therapy aims to reduce the risk of the cancer [...]
Four-year follow-up with lenvatinib plus pembrolizumab for advanced kidney cancer
Further follow-up data from the phase 3 CLEAR study with [...]
